Stock
Ownership of a fraction of a corporation and the right to claim a share of the corporation's assets and profits equal to the amount of stock owned
US listed securityListed on NASDAQ
US headquarteredHeadquartered in South San Francisco, California, United States
Follow
Vaxart Inc
$6.59
VXRT
Mar 3, 12:17:48 PM GMT-5 · USD · NASDAQ · Disclaimer
In the news
Financial performance
| (USD) | Q4 2020 | Year/year change |
|---|---|---|
Revenue | 356.00K | -90.91% |
Net income | -13.86M | -116.27% |
| Diluted EPS | -0.13 | 0.00% |
| Net profit margin | -3,893.54% | -2,279.04% |
| Operating income | -13.36M | -1,792.49% |
| Net change in cash | - | - |
| Cash on hand | 126.87M | 837.97% |
| Cost of revenue | 8.59M | 161.05% |
About
Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. Its development programs for oral vaccine delivery include prophylactic, enteric-coated tablet vaccines for inhibiting norovirus, seasonal influenza, respiratory syncytial virus, and human papillomavirus.
Vaxart has a collaborative development program for oral delivery of a vaccine against universal flu using proprietary antigens from Janssen Pharmaceutica. Wikipedia
Founded
Mar 14, 1969
Website
Employees
49
Key stats
Previous close
The last closing price
$7.14
Day range
The difference between the high and low prices over the past day
$6.53 - $6.94
Year range
The difference between the high and low prices over the past 52 weeks
$1.08 - $24.90
Market cap
A valuation method that multiplies the price of a company's stock by the total number of outstanding shares.
776.10M USD
Volume
The average number of shares traded each day over the past 30 days
23.70M
P/E ratio
The ratio of current share price to trailing twelve month EPS that signals if the price is high or low compared to other stocks
-
Dividend yield
The ratio of annual dividend to current share price that estimates the dividend return of a stock
-
Primary exchange
Listed exchange for this security
NASDAQ
About
Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. Its development programs for oral vaccine delivery include prophylactic, enteric-coated tablet vaccines for inhibiting norovirus, seasonal influenza, respiratory syncytial virus, and human papillomavirus.
Vaxart has a collaborative development program for oral delivery of a vaccine against universal flu using proprietary antigens from Janssen Pharmaceutica. Wikipedia
Founded
Mar 14, 1969
Website
Employees
49
